Literature DB >> 22322359

Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance.

A Blackman1, S May, R A Devasia, F Maruri, C Stratton, T R Sterling.   

Abstract

Microcolony growth of Mycobacterium tuberculosis on agar proportion susceptibility testing is neither well-defined nor previously reported with fluoroquinolone susceptibility testing. We describe here M. tuberculosis microcolony growth with fluoroquinolones, and assess its clinical significance. We screened 797 M. tuberculosis isolates for ofloxacin resistance (2.0 μg/mL) by agar proportion; 19 ofloxacin-resistant and 38 ofloxacin-susceptible isolates were selected for more detailed susceptibility testing with ofloxacin, ciprofloxacin, levofloxacin (all at 2.0 μg/mL) and moxifloxacin (0.5 μg/mL). The 57 isolates were also tested at two concentrations both above and below the critical concentrations. Microcolonies were defined as colonies 0.2-0.4 mm in diameter; confirmed microcolonies were present on repeat testing. Of the 57 isolates tested in detail, 7 grew microcolonies, of which 2 (0.3% of all isolates tested) had confirmed microcolonies on repeat testing (6 tests performed, and microcolonies were present on at least 4). Both M. tuberculosis isolates were ofloxacin-resistant on screening, and had ofloxacin minimum inhibitory concentration (MIC) >8 μg/mL. The five other isolates were ofloxacin-susceptible on screening, but had regular colony growth (i.e., resistance) at the drug concentration that initially resulted in microcolonies (ofloxacin 0.5 or 1.0 μg/mL). Microcolonies were observed infrequently with fluoroquinolone susceptibility testing, but when confirmed, they were associated with drug resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322359      PMCID: PMC3981548          DOI: 10.1007/s10096-012-1552-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Authors:  Alexandra Aubry; Nicolas Veziris; Emmanuelle Cambau; Chantal Truffot-Pernot; Vincent Jarlier; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods.

Authors:  B Madison; B Robinson-Dunn; I George; W Gross; H Lipman; B Metchock; A Sloutsky; G Washabaugh; G Mazurek; J Ridderhof
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Differential growth characteristics and streptomycin susceptibility of virulent and avirulent Mycobacterium tuberculosis strains in a novel fibroblast-mycobacterium microcolony assay.

Authors:  T F Byrd; G M Green; S E Fowlston; C R Lyons
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

5.  Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.

Authors:  Rose A Devasia; Amondrea Blackman; Carolyn May; Svetlana Eden; Teresa Smith; Nancy Hooper; Fernanda Maruri; Charles Stratton; Ayumi Shintani; Timothy R Sterling
Journal:  J Antimicrob Chemother       Date:  2009-03-28       Impact factor: 5.790

6.  Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.

Authors:  Rose A Devasia; Amondrea Blackman; Tebeb Gebretsadik; Marie Griffin; Ayumi Shintani; Carolyn May; Teresa Smith; Nancy Hooper; Fernanda Maruri; Jon Warkentin; Ed Mitchel; Timothy R Sterling
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.